Last update 07 Jul 2025

Cytarabine/Daunorubicin Liposomal

Overview

Basic Info

Drug Type
Small molecule drug, Liposomal Drug
Synonyms
AraC-Daunorubicin CPX-351, Cytarabine:daunorubicin, Daunorubicin Hydrochloride/Cytarabine
+ [9]
Action
inhibitors
Mechanism
DNA-directed DNA polymerase inhibitors, Top II inhibitors(Topoisomerase II inhibitors), DNA synthesis inhibitors
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
RegulationBreakthrough Therapy (United States), Fast Track (United States), Orphan Drug (Japan), Orphan Drug (South Korea)
Login to view timeline

Structure/Sequence

Molecular FormulaC36H42N4O15
InChIKeyHBQCEICSYDCGJG-SZXLQUARSA-N
CAS Registry1256639-86-7

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Treatment related acute myeloid leukaemia
European Union
23 Aug 2018
Treatment related acute myeloid leukaemia
Iceland
23 Aug 2018
Treatment related acute myeloid leukaemia
Liechtenstein
23 Aug 2018
Treatment related acute myeloid leukaemia
Norway
23 Aug 2018
Acute Myeloid Leukemia
United States
03 Aug 2017
Acute Myeloid Leukemia with Myelodysplasia-Related Changes
United States
03 Aug 2017
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
High Risk Myelodysplastic SyndromePhase 3
United States
13 Dec 2012
High Risk Myelodysplastic SyndromePhase 3
Canada
13 Dec 2012
Acute Myeloid Leukemia with FLT3/ITD MutationPhase 2
United States
05 Jul 2022
Acute Myelomonocytic LeukemiaPhase 2
United States
30 Jan 2022
Acute Myelomonocytic LeukemiaPhase 2
United States
30 Jan 2022
Anemia, Refractory, With Excess of BlastsPhase 2
United States
09 Aug 2021
Residual NeoplasmPhase 2
United States
09 Aug 2021
Acute myeloid leukaemia with 11q23 abnormalityPhase 2
United States
30 Dec 2020
IDH1 Mutation Acute Myeloid LeukemiaPhase 2
United States
30 Dec 2020
Myeloproliferative DisordersPhase 2
United States
30 Dec 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
35
Palbociclib+cytarabine+daunorubicin+CPX-351
(Phase I)
pawibhjcxo = ropmtdrrvu uwpibbfmnm (eoixisewtw, wikohbhvdu - juamnpesah)
-
31 May 2025
czuphswcwr = ghjyukupzk ymouztfomt (fqbiprskma, oeirexmzmd - bqteidnetk)
Not Applicable
Acute Myeloid Leukemia
myelodysplasia-related gene mutations
161
wroesucniu(gsxbfuyjrf) = mkbgczvaau ddcqxeniwr (dtkbfwwxwu )
Positive
30 May 2025
Not Applicable
602
smcdnqtnwf(gdinjzmwcb) = zxdpemsqqn fxinsxwhvm (zpslbvmxkn, 12 - 32)
-
14 May 2025
Not Applicable
Acute Myeloid Leukemia
MDS-related gene mutations
85
bkspqcvxxq(cbmffowehb) = oebujvjbsd ithwmmzkmh (gmbzauxpym )
Positive
14 May 2025
Phase 2
Acute Myeloid Leukemia
JAK2 | TP53 | ASXL1 ...
41
pejgnssuua(wdzyflhtxj) = gyacfjtmok faggjhegmw (oebfgandyx, 4.5 - 12)
Positive
14 May 2025
Phase 2
Myelodysplastic Syndromes
ASXL1 | RUNX1 | STAG2 ...
20
ojewqlbtno(qmjfxngcyr) = wpszppuwvo codvciqixr (ogtpswqxqz )
Positive
14 May 2025
Not Applicable
Acute Myeloid Leukemia
myelodysplasia-related gene mutations
161
rvczfwjfod(ykkrcgjmqi) = secphynwyc ewnezkrzmj (gdqfwkntti )
Positive
14 May 2025
Not Applicable
Acute Myeloid Leukemia
TP53 | ASXL1 | BCOR ...
81
koaytfjkrr(xjvhfmtvwd) = uffgciqamy myqenolves (fjxfqvzczy, 10.7 - 19.3)
-
14 May 2025
Phase 2
11
wrbacgqhha(gtfxdnqucr) = mothdgxykf zkohezddeu (juyhyobprd )
Positive
09 Dec 2024
(Adult patients 18 years or older with R/R AML or high-risk MDS harboring an IDH1 mutation)
wrbacgqhha(gtfxdnqucr) = woirrasufx zkohezddeu (juyhyobprd )
Phase 1
8
wudmleccvg(xfvknbdvhi) = observed in 2 patients (1 in Cohort A and 1 in Cohort B) kagyeltmlf (prgtwhoade )
Positive
09 Dec 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free